Figure 1. Chronic verrucous Oka strain VZV in immunocompromised patient.

A. B. Figure 1. Chronic verrucous Oka strain VZV in immunocompromised patient. A) Widespread nonhealing lesions on patient’s right thigh shown approximately four weeks after starting acyclovir therapy. New vesicles continued to erupt in this region as well as distantly (hands, face) while on acyclovir. Of interest, patient originally received varicella vaccine in left thigh but eruption was most severe on right leg. B) Lesions on right foot demonstrate wart-like appearance (arrow) with central umbilication and surrounding chronic erythema characteristic of chronic verrucous VZV.

Figure 1. Chronic verrucous Oka strain VZV in immunocompromised patient.

Figure 1. Chronic verrucous Oka strain VZV in immunocompromised patient.

Presentation Transcript

OKA!!!

Figure 1: Patient Characteristics

OKA

Figure 1. Elongation as a function of strain rate in 4% hydrogen/ nitrogen.

Infections in the Immunocompromised Host

Oka et al. supplementary Figure 1 Top

Figure 1 Multiple complications in a patient with pneumococcal meningitis

Figure 8.1 A simple strain gage.

OKA!!!

Figure S2 A. Strain BSF2608

Genetic differences between VZV wild-type and Oka strains Judith Breuer Professor of Virology

Pneumonia in Immunocompromised Host:-

Figure 1 TLRs and chronic inflammation

Herpesvirus Infections in Immunocompromised Patients

Infections In The Immunocompromised Host

Figure 1 Onychodystrophy in the case patient

Disease emergence in immunocompromised populations

New treatment options for mycotic infections in the immunocompromised patient

Figure 8.1 A simple strain gage.